Exelixis Inc

EXELNASDAQ · USD
68.29USD0.00 (-0.31%)
7810

Exelixis Inc (EXEL) Historical Volatility

EXEL's 30 day historical volatility is 32.14%, in the 48th percentile of readings over the past year. This is an average percentile, meaning Exelixis Inc shares have moved roughly in line with their typical range. EXEL's 30 day implied volatility sits at 35.50%, with an IV Rank of 17.86%, leaving IV 3.36 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.

Read more

Tracking EXEL historical volatility helps you see how much Exelixis Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, EXEL's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor EXEL 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. EXEL's 30 day historical volatility, or EXEL HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing EXEL's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.

Historical Volatility

HV Percentile
48thHV Percentile
Moderate

Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.

Historical Volatility (30d)32.14%

HV Percentile48th

Implied Volatility (30d)35.50%

IV Rank17.86%

IV Minus HV+3.36%

As of Nov 18, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 18, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →